Pricing Log in Create free account
Saturday 17 October 2026 Export TECH’s income statement to Excel — free account

Bio-Techne Corp

TECH Healthcare Biotechnology

Bio-Techne Corp’s revenue for fiscal 2026 (year ended June 2026) was $1.2 billion, roughly unchanged from fiscal 2025. In the quarter to June 2026, revenue grew 1.33%, EPS grew 418.2%, free cash flow fell 6.83% and total debt fell 42.2%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for three consecutive years.

72.54 0.02 +0.03%
Market cap
$11.4B
P/E
62.0×
Fwd P/E
37.6×
Dividend yield
0.44%
F-score
9/9
Altman Z
15.50
Beneish M
−2.52
Dividend safety
78/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Bio-Techne Corp 10-Q filed May 6, 2026

Fiscal Q3 2026 · Period ended Mar 31, 2026 · Filed · accepted 4:31 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Feb 4, 2026: 11 modified; 19 with only figures updated

  1. Modified · Net Sales

    Consolidated net sales for the quarter ended DecemberMarch 31, 2025 remained flat at2026 decreased 2% to $295.9311.4 million compared to the same prior year period. Consolidated net sales for the sixnine months ended DecemberMarch 31, 20252026 were $582.4893.8 million, a decrease of 1% from the same prior year period. Organic revenue for the quarter ended DecemberMarch 31, 2025 remained flat2026 decreased 2% compared to the prior year. Foreign currency exchange had a favorable impact of 2% and non-recurring prior year revenue from a business held-for-sale had an unfavorable impact of 2%. Organic revenue for the sixnine months ended DecemberMarch 31, 2025 remained flat2026 decreased 1% compared to the prior year. Foreign currency exchange had a favorable impact of 12% and non-recurring prior year revenue from a business held-for-sale had an unfavorable impact of 2%. Organic revenue for the quarter ended DecemberMarch 31, 20252026 was primarily driven by favorable performance by our Diagnostics and Spatial Biology portfolio unfavorable volume and product mix in our Protein Sciences segment, partially offset by unfavorable product mix favorable performance in our Protein Sciences segmentDiagnostics and Spatial Biology portfolio.

10 more changes in this Item, word by word, in Powerpack.

Powerpack